🇺🇸 FDA
Pipeline program

0.9% sodium chloride - inhalation solution, ARO-MUC5AC Inhalation Solution

AROMUC5AC-1001

Phase 2 small_molecule active

Quick answer

0.9% sodium chloride - inhalation solution, ARO-MUC5AC Inhalation Solution for Asthma and Chronic obstructive pulmonary disease is a Phase 2 program (small_molecule) at Arrowhead Pharmaceuticals Ireland Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Arrowhead Pharmaceuticals Ireland Limited
Indication
Asthma and Chronic obstructive pulmonary disease
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials